SEARCH:   Advanced

Blood, 15 August 2005, Vol. 106, No. 4, pp. 1341-1345. Prepublished online as a Blood First Edition Paper on May 10, 2005; DOI 10.1182/blood-2004-11-4477. This Article Full Text (PDF) All Versions of this Article: 2004-11-4477v1 106/4/1341    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tassone, P. Articles by Munshi, N. C Search for Related Content PubMed PubMed Citation Articles by Tassone, P. Articles by Munshi, N. C Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 29, 2004 Accepted March 6, 2005 A SCID-hu in vivo model for human Waldenstrom macroglobulinemia Pierfrancesco Tassone, Paola Neri, Jeffery L Kutok, Olivier Tournilhac, Daniel D Santos, Evdoxia Hatjiharissi, Vidit Munshi, Salvatore Venuta, Kenneth C Anderson, Steven P Treon, and Nikhil C Munshi* Dana-Farber Cancer Institute, Boston, MA, USA; VA Boston Healthcare System, Boston, MA, USA; University of 'Magna Graecia' and Cancer Center, Catanzaro, Italy, Italy Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, USA Dana-Farber Cancer Institute, Boston, MA, USA VA Boston Healthcare System, Boston, MA, USA University of 'Magna Graecia' and Cancer Center, Catanzaro, Italy, Italy Dana-Farber Cancer Institute, Boston, MA, USA; VA Boston Healthcare System, Boston, MA, USA * Corresponding author; email: Nikhil_Munshi{at}dfci.harvard.edu. The pre-clinical evaluation of investigational agents for Waldenstrom macroglobulinemia (WM) has been limited by the lack of in vivo models using explanted patient cells. We describe a novel in vivo model of human WM in immunodeficient mice implanted with human fetal bone chips (SCID-hu mice) into which WM cells from patient bone marrow are engrafted directly into the human bone marrow (huBM) microenvironment. WM cells in SCID-hu mice produced monoclonal human paraprotein (IgM and/or or chain) detectable in mice sera. Immunohistochemical analysis of human bone retrieved from SCID-hu mice showed infiltration with CD20+, IgM+, and monotypic light chain+ lymphoplasmacytic cells. Mast cells were observed to be associated with the infiltrate in these sections. Treatment of SCID-hu mice bearing WM with Rituximab induced tumor regression, associated with decreased of serum paraprotein. This model, therefore, recapitulates the in vivo biology of WM and allows the study of novel investigational drugs targeting WM cells in the huBM milieu. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: A "not so micro" model for a "macro" problem Rafael Fonseca Blood 2005 106: 1143-1144. [Full Text] [PDF] This article has been cited by other articles: A. W. Ho, E. Hatjiharissi, B. T. Ciccarelli, A. R. Branagan, Z. R. Hunter, X. Leleu, O. Tournilhac, L. Xu, K. O'Connor, R. J. Manning, et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia Blood, December 1, 2008; 112(12): 4683 - 4689. [Abstract] [Full Text] [PDF] A.-S. Moreau, X. Jia, H. T. Ngo, X. Leleu, G. O'Sullivan, Y. Alsayed, A. Leontovich, K. Podar, J. Kutok, J. Daley, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia Blood, June 1, 2007; 109(11): 4964 - 4972. [Abstract] [Full Text] [PDF] W. Dalton and K. C. Anderson Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma. Clin. Cancer Res., November 15, 2006; 12(22): 6603 - 6610. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020